Does the media prefer VSTM or BCRX?

In the previous week, BioCryst Pharmaceuticals had 16 more articles in the media than Verastem. MarketBeat recorded 20 mentions for BioCryst Pharmaceuticals and 4 mentions for Verastem. BioCryst Pharmaceuticals' average media sentiment score of 1.24 beat Verastem's score of 0.81 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, NUVB or VSTM?

Nuvation Bio has higher earnings, but lower revenue than Verastem. Nuvation Bio is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvation Bio $62.90M 36.45 -$204.63M -$0.44 N/A Verastem $87.53M 7.37 -$209.47M -$2.66 N/A

Is NUVB or VSTM more profitable?

Nuvation Bio has a net margin of -88.18% compared to Verastem's net margin of -231.59%. Nuvation Bio's return on equity of -46.59% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Nuvation Bio -88.18% -46.59% -22.01% Verastem -231.59% -467.49% -94.54%

Does the media refer more to NUVB or VSTM?

In the previous week, Verastem had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 4 mentions for Verastem and 1 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.92 beat Verastem's score of 0.81 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VSTM or KOD more profitable?

Kodiak Sciences has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Kodiak Sciences' return on equity of -273.23% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% Kodiak Sciences N/A -273.23% -85.48%

Does the media prefer VSTM or KOD?

In the previous week, Kodiak Sciences had 3 more articles in the media than Verastem. MarketBeat recorded 7 mentions for Kodiak Sciences and 4 mentions for Verastem. Kodiak Sciences' average media sentiment score of 1.55 beat Verastem's score of 0.81 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is PHVS or VSTM more profitable?

Pharvaris has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Pharvaris' return on equity of -61.40% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -61.40% -56.00% Verastem -231.59% -467.49% -94.54%

Does the media refer more to PHVS or VSTM?

In the previous week, Pharvaris had 5 more articles in the media than Verastem. MarketBeat recorded 9 mentions for Pharvaris and 4 mentions for Verastem. Pharvaris' average media sentiment score of 1.47 beat Verastem's score of 0.81 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VERA or VSTM?

In the previous week, Vera Therapeutics had 2 more articles in the media than Verastem. MarketBeat recorded 6 mentions for Vera Therapeutics and 4 mentions for Verastem. Vera Therapeutics' average media sentiment score of 0.89 beat Verastem's score of 0.81 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Verastem (VSTM) Competitors

$7.12 -0.10 (-1.39%)

As of 02:27 PM Eastern

Compare

VSTM vs. BCRX, NUVB, KOD, PHVS, and VERA

Should you buy Verastem stock or one of its competitors? Verastem's main competitors and comparable companies include BioCryst Pharmaceuticals (BCRX), Nuvation Bio (NUVB), Kodiak Sciences (KOD), Pharvaris (PHVS), and Vera Therapeutics (VERA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Verastem compare to BioCryst Pharmaceuticals?

Verastem (NASDAQ:VSTM) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

In the previous week, BioCryst Pharmaceuticals had 16 more articles in the media than Verastem. MarketBeat recorded 20 mentions for BioCryst Pharmaceuticals and 4 mentions for Verastem. BioCryst Pharmaceuticals' average media sentiment score of 1.24 beat Verastem's score of 0.81 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Verastem presently has a consensus target price of $13.83, suggesting a potential upside of 94.29%. BioCryst Pharmaceuticals has a consensus target price of $20.60, suggesting a potential upside of 115.48%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

BioCryst Pharmaceuticals has higher revenue and earnings than Verastem. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$87.53M	7.37	-$209.47M	-$2.66	N/A
BioCryst Pharmaceuticals	$874.84M	2.79	$263.86M	-$1.50	N/A

Verastem has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

88.4% of Verastem shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Verastem's net margin of -231.59%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Summary

BioCryst Pharmaceuticals beats Verastem on 12 of the 17 factors compared between the two stocks.

How does Verastem compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Verastem had 3 more articles in the media than Nuvation Bio. MarketBeat recorded 4 mentions for Verastem and 1 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.92 beat Verastem's score of 0.81 indicating that Nuvation Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvation Bio has a net margin of -88.18% compared to Verastem's net margin of -231.59%. Nuvation Bio's return on equity of -46.59% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Verastem	-231.59%	-467.49%	-94.54%

Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Verastem has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 1.9% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvation Bio has higher earnings, but lower revenue than Verastem. Nuvation Bio is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	36.45	-$204.63M	-$0.44	N/A
Verastem	$87.53M	7.37	-$209.47M	-$2.66	N/A

Nuvation Bio currently has a consensus target price of $13.00, indicating a potential upside of 99.08%. Verastem has a consensus target price of $13.83, indicating a potential upside of 94.29%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Nuvation Bio beats Verastem on 11 of the 17 factors compared between the two stocks.

How does Verastem compare to Kodiak Sciences?

Verastem (NASDAQ:VSTM) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Kodiak Sciences has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Kodiak Sciences' return on equity of -273.23% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
Kodiak Sciences	N/A	-273.23%	-85.48%

88.4% of Verastem shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 1.9% of Verastem shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Verastem has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Verastem has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$87.53M	7.37	-$209.47M	-$2.66	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

Verastem currently has a consensus price target of $13.83, suggesting a potential upside of 94.29%. Kodiak Sciences has a consensus price target of $48.14, suggesting a potential upside of 29.52%. Given Verastem's stronger consensus rating and higher possible upside, equities analysts clearly believe Verastem is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Kodiak Sciences had 3 more articles in the media than Verastem. MarketBeat recorded 7 mentions for Kodiak Sciences and 4 mentions for Verastem. Kodiak Sciences' average media sentiment score of 1.55 beat Verastem's score of 0.81 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Verastem and Kodiak Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Verastem compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Pharvaris has higher earnings, but lower revenue than Verastem. Pharvaris is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A
Verastem	$87.53M	7.37	-$209.47M	-$2.66	N/A

Pharvaris has a beta of -2.31, meaning that its stock price is 331% less volatile than the broader market. Comparatively, Verastem has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

88.4% of Verastem shares are held by institutional investors. 1.9% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Pharvaris had 5 more articles in the media than Verastem. MarketBeat recorded 9 mentions for Pharvaris and 4 mentions for Verastem. Pharvaris' average media sentiment score of 1.47 beat Verastem's score of 0.81 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Pharvaris' return on equity of -61.40% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-61.40%	-56.00%
Verastem	-231.59%	-467.49%	-94.54%

Pharvaris presently has a consensus price target of $51.08, indicating a potential upside of 48.39%. Verastem has a consensus price target of $13.83, indicating a potential upside of 94.29%. Given Verastem's higher probable upside, analysts clearly believe Verastem is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Pharvaris beats Verastem on 8 of the 15 factors compared between the two stocks.

How does Verastem compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Verastem (NASDAQ:VSTM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Vera Therapeutics has a net margin of 0.00% compared to Verastem's net margin of -231.59%. Vera Therapeutics' return on equity of -84.13% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Verastem	-231.59%	-467.49%	-94.54%

Verastem has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Verastem	$87.53M	7.37	-$209.47M	-$2.66	N/A

Vera Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Verastem has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Vera Therapeutics currently has a consensus target price of $81.15, suggesting a potential upside of 140.88%. Verastem has a consensus target price of $13.83, suggesting a potential upside of 94.29%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Vera Therapeutics had 2 more articles in the media than Verastem. MarketBeat recorded 6 mentions for Vera Therapeutics and 4 mentions for Verastem. Vera Therapeutics' average media sentiment score of 0.89 beat Verastem's score of 0.81 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 1.9% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vera Therapeutics beats Verastem on 11 of the 15 factors compared between the two stocks.

Get Verastem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VSTM vs. The Competition

Export

Metric	Verastem	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$644.81M	$3.91B	$7.12B	$12.81B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-2.68	11.80	272.85	25.44
Price / Sales	7.37	1,393.89	686.01	122.49
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	9.62	16.73	11.02	6.33
Net Income	-$209.47M	-$22.71M	$3.47B	$349.46M
7 Day Performance	3.79%	2.20%	0.97%	-0.28%
1 Month Performance	22.76%	12.33%	7.95%	4.18%
1 Year Performance	-23.03%	54.03%	23.79%	14.55%

Verastem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VSTM Verastem	3.17 of 5 stars	$7.12 -1.4%	$13.83 +94.3%	-21.9%	$644.81M	$87.53M	N/A	50
BCRX BioCryst Pharmaceuticals	3.2553 of 5 stars	$9.68 +1.4%	$20.60 +112.8%	+18.2%	$2.44B	$874.84M	N/A	530	Positive News Analyst Downgrade
NUVB Nuvation Bio	3.7038 of 5 stars	$6.76 -2.5%	$13.00 +92.5%	+125.2%	$2.43B	$62.90M	N/A	60
KOD Kodiak Sciences	2.4629 of 5 stars	$37.22 -2.9%	$48.14 +29.3%	+317.3%	$2.41B	N/A	N/A	90	Positive News
PHVS Pharvaris	3.8999 of 5 stars	$37.31 +2.9%	$51.08 +36.9%	+63.1%	$2.37B	N/A	N/A	30	Positive News Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VSTM) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verastem (VSTM) Competitors

VSTM vs. BCRX, NUVB, KOD, PHVS, and VERA

How does Verastem compare to BioCryst Pharmaceuticals?

Summary

How does Verastem compare to Nuvation Bio?

Summary

How does Verastem compare to Kodiak Sciences?

Summary

How does Verastem compare to Pharvaris?

Summary

How does Verastem compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verastem (VSTM) Competitors

VSTM vs. BCRX, NUVB, KOD, PHVS, and VERA

How does Verastem compare to BioCryst Pharmaceuticals?

Does the media prefer VSTM or BCRX?

Do analysts recommend VSTM or BCRX?

Which has stronger earnings and valuation, VSTM or BCRX?

Which has more volatility and risk, VSTM or BCRX?

Do insiders & institutionals hold more shares of VSTM or BCRX?

Is VSTM or BCRX more profitable?

Summary

How does Verastem compare to Nuvation Bio?

Does the media refer more to NUVB or VSTM?

Is NUVB or VSTM more profitable?

Which has more risk and volatility, NUVB or VSTM?

Do insiders & institutionals have more ownership in NUVB or VSTM?

Which has better earnings & valuation, NUVB or VSTM?

Do analysts recommend NUVB or VSTM?

Summary

How does Verastem compare to Kodiak Sciences?

Is VSTM or KOD more profitable?

Do institutionals and insiders have more ownership in VSTM or KOD?

Which has more risk and volatility, VSTM or KOD?

Which has preferable valuation and earnings, VSTM or KOD?

Do analysts rate VSTM or KOD?

Does the media prefer VSTM or KOD?

Summary

How does Verastem compare to Pharvaris?

Which has higher earnings and valuation, PHVS or VSTM?

Which has more volatility and risk, PHVS or VSTM?

Do institutionals and insiders believe in PHVS or VSTM?

Does the media refer more to PHVS or VSTM?

Is PHVS or VSTM more profitable?

Do analysts prefer PHVS or VSTM?

Summary

How does Verastem compare to Vera Therapeutics?

Is VERA or VSTM more profitable?

Which has better valuation and earnings, VERA or VSTM?

Which has more risk & volatility, VERA or VSTM?

Do analysts rate VERA or VSTM?

Does the media favor VERA or VSTM?

Do institutionals & insiders hold more shares of VERA or VSTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM vs. The Competition

Verastem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools